首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

2126328

臨床定序市場：策略性洞察與預測（2026-2035 年）

Clinical Sequencing Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月03日 | 出版商:

Knowledge Sourcing Intelligence | 英文 175 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

臨床定序市場預計將從 2026 年的 70.1 億美元成長到 2035 年的 243.3 億美元，複合年成長率為 14.8%。

臨床定序市場正經歷重大變革，其驅動力源自於精準醫療的模式轉移以及基因組資訊在常規臨床實踐中的整合。這一市場演變的特點是，人們日益認知到，全面的分子特徵分析對於疾病診斷、治療方案選擇、治療監測以及跨多個醫學專科的預防醫學至關重要。次世代定序技術、生物資訊學創新和人工智慧的融合，使得基因組分析更加快速、準確且日益普及。隨著精準醫療計畫在國家和機構層面的擴展，定序正逐步融入醫療保健系統的常規臨床工作流程。這項轉變需要標準化的檢查室基礎設施、檢驗的定序方法、臨床生物資訊流程以及多學科基因組分析團隊。隨著分子層級分層能夠改善患者選擇和生物標記的識別，製藥公司在整個藥物研發過程中對臨床定序的依賴程度也不斷提高。隨著對長讀長定序技術、人工智慧驅動的分析平台和分散式定序解決方案的大量投資，臨床定序正逐漸成為支持精準醫療持續發展的基礎技術。

市場促進因素

精準腫瘤學是臨床定序市場的主要驅動力。癌症治療越來越依賴分子譜分析，因為基因組突變決定了標靶治療和免疫腫瘤療法的適用性。隨著基於生物標記的治療途徑不斷擴展，醫院和癌症中心正在將全面的基因測序整合到其常規診斷流程中。臨床檢查室擴充性的定序平台，能夠以高分析精度檢測單核苷酸多態性（SNV）、插入、缺失、拷貝數變異和基因融合。技術開發人員正透過推動工作流程自動化、擴大與伴隨診斷的整合以及加強腫瘤特異性定序產品線來響應這一需求，從而推動臨床定序應用的持續成長。全基因測序定序和全EXOME定序的應用進一步加速了罕見疾病診斷市場的成長。由於傳統診斷測試僅評估有限的基因組區域，罕見遺傳疾病往往無法確診。醫療機構正擴大採用全基因測序定序和全EXOME定序來提高診斷率，同時縮短冗長的診斷流程。早期分子診斷可減少不必要的檢測，並支持對受影響個體進行個人化臨床管理。醫療機構正在擴展整合臨床遺傳學、生物資訊學和遺傳諮詢服務的多學科基因組醫學計畫。政府基因組醫學計畫正在加強臨床基礎設施建設和部署。國家精準醫療策略鼓勵系統性地定序基因組訊息，以支持疾病預防、研究和醫療保健規劃。隨著個人化醫療的不斷發展，各國政府正在投資定序實驗室、臨床基因組學網路、數位健康基礎設施和基因組數據儲存庫。標準化實施需要法律規範、檢查室認證、人力資源開發和安全的基因組資料管治。生物資訊學的創新正在提高臨床效用和解讀準確性。臨床定序會產生複雜的基因組資料集，需要準確的解讀才能應用於病患管理。隨著各臨床專科定序量的持續成長，醫療機構正在採用基於雲端的生物資訊平台。變異解讀軟體整合了精心整理的資料庫、已發表的證據、臨床指南和表現型訊息，以提高診斷的可靠性。技術供應商正在擴大整個實驗室操作的自動化程度，同時將人工智慧 (AI) 融入判讀工作流程中。

市場限制因素

建構定序基礎設施的高昂成本（需要專用設備、生物資訊能力和熟練人員）持續限制資源匱乏的醫療機構採用定序技術。巨額資本投入對小規模的醫療機構和診所而言是一大障礙。各國監管政策的差異，導致檢查室自建檢測、伴隨診斷和體外診斷定序平台的證據要件各不相同，從而為商業化帶來挑戰。缺乏統一標準進一步加劇了進入全球市場的困難。隨著臨床定序計畫的擴展，基因組資料隱私和網路安全問題依然備受關注，因為需要安全的長期儲存、存取控制和合規性。基因組資訊的高度敏感度也帶來了更高的管治要求。此外，缺乏專業的生物資訊學和基因組分析技術也限制了定序平台的有效利用，並限制了許多醫療機構的擴充性。

依產品類型
- 裝置
- 試劑盒和試劑
- 軟體服務
依技術類型
- 全基因組定序（WGS）
- 全EXOME定序（WES）
- 目標基因定序
- 其他
依檢體類型
- 血
- 組織
- 唾液
- 骨髓
- 其他檢體類型
透過使用
- 瘤
- 罕見疾病和遺傳疾病
- 生殖健康
- 感染疾病
- 神經病變
- 心血管疾病
- 其他
最終用戶
- 醫院
- 臨床診斷檢測實驗室
- 學術和研究醫療中心
- 其他

第10章：全球臨床定序市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球臨床定序市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
中國
日本
印度
韓國
澳洲
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

Oxford Nanopore Technologies
BGI Group
QIAGEN NV
Bio-Rad Laboratories
Takara Bio Inc.
Oxford Nanopore Technologies plc
Agilent Technologies, Inc.
Element Biosciences
Eurofins Genomics
Ultima Genomics

第14章全球臨床定序市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009041

The Clinical Sequencing Market is expected to grow at a CAGR of 14.8% from a market value of USD 7.01 billion in 2026 to USD 24.33 billion in 2035.

The clinical sequencing market is undergoing significant transformation driven by the paradigm shift toward precision medicine and the integration of genomic information into routine clinical practice. The market's evolution is characterized by the growing recognition that comprehensive molecular characterization is essential for disease diagnosis, treatment selection, therapeutic monitoring, and preventive healthcare across multiple medical specialties. The convergence of next-generation sequencing technologies, bioinformatics innovation, and artificial intelligence is enabling faster, more accurate, and increasingly accessible genomic analysis. Healthcare systems are incorporating sequencing into routine clinical workflows as precision medicine initiatives expand nationally and institutionally. This transition requires standardized laboratory infrastructure, validated sequencing assays, clinical bioinformatics pipelines, and multidisciplinary genomic interpretation teams. Pharmaceutical companies increasingly depend on clinical sequencing throughout drug development because molecular stratification improves patient selection and biomarker identification. The market is witnessing significant investment in long-read sequencing technologies, AI-enabled interpretation platforms, and decentralized sequencing solutions, positioning clinical sequencing as a foundational technology supporting the continued evolution of precision healthcare.

Market Drivers

Precision oncology represents the primary driver for the clinical sequencing market. Cancer treatment increasingly depends on molecular profiling because genomic alterations determine eligibility for targeted therapies and immuno-oncology approaches. Hospitals and cancer centers are incorporating comprehensive genomic sequencing into routine diagnostic workflows as biomarker-guided treatment pathways continue expanding. Clinical laboratories require scalable sequencing platforms capable of detecting single-nucleotide variants, insertions, deletions, copy number alterations, and gene fusions with high analytical accuracy. Technology developers are responding by improving workflow automation, expanding companion diagnostic collaborations, and strengthening oncology-focused sequencing portfolios, resulting in sustained growth in clinical sequencing utilization. Rare disease diagnosis is further accelerating market growth through adoption of whole genome and whole exome sequencing. Rare genetic disorders frequently remain undiagnosed because conventional diagnostic testing evaluates limited genomic regions. Healthcare providers are increasingly adopting whole genome and whole exome sequencing to improve diagnostic yield while shortening prolonged diagnostic journeys. Earlier molecular diagnosis reduces unnecessary investigations and supports individualized clinical management for affected patients. Healthcare institutions are expanding multidisciplinary genomic medicine programs that integrate clinical genetics, bioinformatics, and genetic counseling services. Government genomic medicine programs are strengthening clinical infrastructure and adoption. National precision medicine strategies encourage systematic genomic integration because population-scale sequencing supports disease prevention, research, and healthcare planning. Governments are investing in sequencing laboratories, clinical genomics networks, digital health infrastructure, and genomic data repositories as personalized healthcare initiatives continue expanding. Standardized implementation requires regulatory oversight, laboratory accreditation, workforce development, and secure genomic data governance. Bioinformatics innovation is improving clinical utility and interpretation accuracy. Clinical sequencing generates complex genomic datasets that require accurate interpretation before influencing patient management. Healthcare organizations are adopting cloud-enabled bioinformatics platforms as sequencing volume continues increasing across clinical specialties. Variant interpretation software integrates curated databases, published evidence, clinical guidelines, and phenotype information to improve diagnostic confidence. Technology providers are incorporating artificial intelligence into interpretation workflows while expanding automation across laboratory operations.

Market Restraints

High implementation costs continue limiting adoption among resource-constrained healthcare institutions because sequencing infrastructure requires specialized equipment, bioinformatics capabilities, and skilled personnel. The significant capital investment creates barriers for smaller facilities and practices. Regulatory variability across countries creates commercialization challenges because evidence requirements differ for laboratory-developed tests, companion diagnostics, and in vitro diagnostic sequencing platforms. The lack of harmonized standards increases complexity for global market access. Genomic data privacy and cybersecurity concerns remain significant because expanding clinical sequencing programs require secure long-term storage, controlled access, and regulatory compliance. The sensitive nature of genomic information creates additional governance requirements. Shortages of specialized bioinformatics and genomic interpretation expertise constrain efficient utilization of sequencing platforms, limiting scalability in many healthcare settings.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of comprehensive genomic approaches. Whole genome sequencing provides comprehensive genomic characterization because it evaluates coding and non-coding regions within a single assay. Healthcare institutions are increasingly adopting WGS for rare diseases, oncology, neonatal intensive care, and complex inherited disorders where targeted approaches may overlook clinically relevant variants. Larger datasets require sophisticated bioinformatics infrastructure and standardized interpretation pipelines before influencing patient care. Technology providers are reducing sequencing costs while improving throughput and computational efficiency. Whole exome sequencing offers a cost-effective approach for protein-coding region analysis, while targeted gene sequencing provides focused analysis for specific clinical indications. Long-read sequencing technologies are gaining clinical interest because structural variants, repeat expansions, and complex genomic rearrangements remain difficult to characterize using conventional short-read sequencing. The segment analysis reveals that kits and reagents represent the largest recurring revenue component because every sequencing workflow depends upon sample preparation, library construction, enrichment chemistry, amplification, quality control, and sequencing consumables. Clinical laboratories are increasing testing volumes as precision medicine programs continue expanding across oncology and inherited disease diagnostics. Oncology remains the leading application because molecular biomarkers increasingly determine treatment selection across multiple cancer types. Cancer centers are incorporating comprehensive genomic profiling into routine diagnostic workflows as targeted therapies and immunotherapies continue expanding. Rare and inherited diseases constitute another major demand segment because conventional diagnostic approaches frequently fail to identify causative genetic variants. Reproductive health applications continue expanding through carrier screening, preimplantation genetic testing, prenatal diagnosis, and non-invasive genomic assessment. Clinical diagnostic laboratories represent key end users, with hospitals and academic medical centers expanding genomic medicine programs. The integration of AI is becoming increasingly important because variant interpretation remains one of the largest operational challenges. AI is supporting automated evidence synthesis, phenotype correlation, and pathogenicity classification within clinical reporting systems, improving reporting consistency across laboratories.

Competitive and Strategic Outlook

The competitive landscape features established sequencing technology providers alongside specialized genomics and diagnostic companies. Oxford Nanopore Technologies differentiates itself through nanopore-based long-read sequencing that enables real-time analysis of DNA and RNA while supporting portable and high-throughput applications, continuing to expand its clinical sequencing portfolio by improving sequencing accuracy, automation, and regulatory validation. BGI Group has established a broad sequencing ecosystem spanning clinical diagnostics, population genomics, reproductive health, and oncology, supported by high-throughput sequencing capabilities, continuing to strengthen its clinical sequencing presence through integrated laboratory services and international collaborations. QIAGEN combines sample preparation technologies, molecular diagnostics, bioinformatics, and next-generation sequencing solutions, enabling end-to-end clinical genomic workflows, expanding companion diagnostics and clinical interpretation capabilities through strategic partnerships. Bio-Rad Laboratories leverages its expertise in molecular biology, digital PCR, and life science research to support high-quality genomic testing workflows, continuing to invest in sequencing-compatible reagents and precision diagnostics. Takara Bio focuses on genomics, cell therapy, and molecular biology technologies with a strong portfolio of sequencing reagents and sample preparation solutions. Agilent Technologies offers integrated genomics solutions, including target enrichment, quality control, automation, and bioinformatics for clinical sequencing laboratories. Companies are pursuing product portfolio expansion through innovation in long-read sequencing, AI-enabled interpretation, and decentralized sequencing solutions. Strategic collaborations between sequencing technology providers, pharmaceutical manufacturers, and clinical laboratories are increasing, driven by the need for companion diagnostic development and biomarker identification. Recent key developments include GeneCentric launching ExpressCT Rewind(TM), a retrospective fragmentomics analysis service applying its pipeline to existing DNA sequencing data. Roche announced the launch of AXELIOS 1, a transformative NGS platform powered by sequencing by expansion technology. Meridian Bioscience and 4bases announced a collaboration to enable rapid, globally scalable NGS workflows. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding. Mergers and acquisitions are occurring as larger players seek to expand market presence and technology capabilities.

Short Conclusion

The clinical sequencing market is positioned for sustained growth driven by the convergence of precision oncology, rare disease diagnosis, government genomic initiatives, and technological innovation. The transition from specialized genomic testing toward routine clinical practice represents a fundamental shift in healthcare delivery. While challenges related to high implementation costs, regulatory variability, and data privacy persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with clinical sequencing evolving into a foundational technology supporting earlier diagnosis, personalized treatment selection, and data-driven clinical decision-making across oncology, rare diseases, reproductive health, infectious diseases, and inherited disorders.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Clinical Sequencing Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Clinical Sequencing Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Disease Burden and Clinical Need for Genomic Testing
3.8 Clinical Sequencing Workflow Overview
3.9 Testing Volume Analysis
3.10 Adoption Analysis Across Clinical Settings
3.11 Precision Medicine and Personalized Healthcare Landscape

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Next-Generation Sequencing Technology Advancements
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 AI Integration in Clinical Sequencing
6.6 Digital Health and Clinical Decision Support Integration

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Clinical Sequencing Market Landscape Analysis

8.1 Analysis by Sequencing Technology
8.2 Analysis by Sequencing Application
8.3 Analysis by Test Type
8.4 Analysis by Sample Type
8.5 Analysis by Clinical Indication
8.6 Analysis by End User

9. Global Clinical Sequencing Market Segment Analysis (2021-2035)

9.1 By Product Type
- 9.1.1 Instruments
- 9.1.2 Kits & Reagents
- 9.1.3 Software & Services
9.2 By Technology Type
- 9.2.1 Whole Genome Sequencing (WGS)
- 9.2.2 Whole Exome Sequencing (WES)
- 9.2.3 Targeted Gene Sequencing
- 9.2.4 Others
9.3 By Sample Type
- 9.3.1 Blood
- 9.3.2 Tissue
- 9.3.3 Saliva
- 9.3.4 Bone Marrow
- 9.3.5 Other Sample Types
9.4 By Application
- 9.4.1 Oncology
- 9.4.2 Rare & Inherited Diseases
- 9.4.3 Reproductive Health
- 9.4.4 Infectious Diseases
- 9.4.5 Neurological Disorders
- 9.4.6 Cardiovascular Diseases
- 9.4.7 Others
9.5 By End User
- 9.5.1 Hospitals
- 9.5.2 Clinical Diagnostic Laboratories
- 9.5.3 Academic & Research Medical Centers
- 9.5.4 Others

10. Global Clinical Sequencing Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Clinical Sequencing Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Netherlands
11.9 China
11.10 Japan
11.11 India
11.12 South Korea
11.13 Australia
11.14 Brazil
11.15 Saudi Arabia

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 Oxford Nanopore Technologies
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 BGI Group
13.3 QIAGEN N.V.
13.4 Bio-Rad Laboratories
13.5 Takara Bio Inc.
13.6 Oxford Nanopore Technologies plc
13.7 Agilent Technologies, Inc.
13.8 Element Biosciences
13.9 Eurofins Genomics
13.10 Ultima Genomics